Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MALACTRES

Financiado

Cerrado

Multi drug resistance in malaria under combination therapy Assessment of specif...

Multi drug resistance in malaria under combination therapy Assessment of specific markers and development of innovative rapid and simple diagnostics This project aims to assess specific P. falciparum genetic markers for resistance to artemisinin-based combinations (ACT), and to develop innovative, rapid and simple diagnostics for malaria and these markers. Specific objectives... ver más

30/06/2013

Royal Tropical Ins...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

HET KONINKLIJK INSTITUUT VOOR DE TROPEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2013-06-30 No tenemos la información de la convocatoria

0% 75% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

Royal Tropical Institute (KI...

0.00€ | Lider

ITM

N.D. | Participante

CENTRE MURAZ

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

MALARES Genetics of Resistance to Malaria Parasites in the Mosquito... 1M€ Cerrado

PFSEXOME Identification of protein kinases and signalling pathways im... 183K€ Cerrado

GENETICHTS REVEAL PF Genetic High Throughput Screenings by random mutagenesis to... 100K€ Cerrado

PTQ2023-012956 GENOMETAD: Genómica de cepas resistentes de P. falciparum pa... 99K€ Cerrado

MALARIA TARGETS ID Mapping the Targets of Antimalarial Compounds Through Chemic... 100K€ Cerrado

INTERMALTRAINING Intervention strategies against malaria 3M€ Cerrado

Líder del proyecto

HET KONINKLIJK INSTITUUT VOOR DE TROPEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto This project aims to assess specific P. falciparum genetic markers for resistance to artemisinin-based combinations (ACT), and to develop innovative, rapid and simple diagnostics for malaria and these markers. Specific objectives are: • To develop and evaluate in disease endemic countries accurate low-tech molecular diagnostic tests. • To identify alleles of candidate resistance genes associated with increased transmission success of P. falciparum after ACT treatment in completed clinical trials (endpoints at gametocyte or infected mosquito level). • To conduct ACT treatment trials with transmission endpoints, and measure impact of resistance-associated alleles on gametocyte emergence, and on the infectiousness of gametocyte-positive or randomly-selected treated individuals to Anopheles mosquitoes. • To measure ACT efficacy using in vivo treatment trials, and in vitro drug sensitivity testing of natural parasite isolates. The impact of candidate resistance markers will be measured in patients with treatment failure, and in parasites with reduced in vitro sensitivity. • To develop new low-tech diagnostic tools able to demonstrate the presence of mutations conferring drug resistance in the Plasmodium population, particularly those markers validated by the project. • To investigate commercial value aspects of developed tests. The project will move our knowledge of ACT resistance forward in 2 complementary ways: 1) In order to identify and validate genetic markers for ACT resistance, we will use our unprecedented access to parasites isolated both from ACT-treated individuals and from mosquitoes fed on blood from ACT-treated individuals. 2) we will develop and validate simple tests in new formats for detection of these and other markers of relevance, and for rapid detection of persisting parasites in treated patients. The work is a balanced mix of clinical field work, laboratory research and (commercial) test development and linked to EU initiative EDCTP.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores